UGIH‐related mortality · people with acute UGIH
1 finding from 1 review
UGIH‐related mortality · people with acute UGIH
1 finding from 1 review
SAEs · people with acute UGIH
1 finding from 1 review
All‐cause mortality · people with acute UGIH
It is very uncertain whether erythromycin changes all‐cause mortality compared with nasogastric tube lavage (very low certainty).
1 finding from 1 review
Visualisation of gastric mucosa · people with acute UGIH
It is very uncertain whether erythromycin changes visualisation of gastric mucosa compared with nasogastric tube lavage (very low certainty).
1 finding from 1 review
NSAEs · people with acute UGIH
It is very uncertain whether erythromycin changes NSAEs compared with nasogastric tube lavage (very low certainty).
1 finding from 1 review
SAEs · people with acute UGIH
It is very uncertain whether erythromycin changes SAEs compared with placebo (very low certainty).
1 finding from 1 review
Rebleeding · people with acute UGIH
It is very uncertain whether erythromycin changes rebleeding compared with nasogastric tube lavage (very low certainty).
1 finding from 1 review
Blood transfusion · people with acute UGIH
1 finding from 1 review
All‐cause mortality · people with acute UGIH
It is very uncertain whether erythromycin changes all‐cause mortality compared with placebo (very low certainty).
1 finding from 1 review
Visualisation of gastric mucosa · people with acute UGIH
1 finding from 1 review
NSAEs · people with acute UGIH
It is very uncertain whether erythromycin changes NSAEs compared with placebo (very low certainty).
1 finding from 1 review
Rebleeding · people with acute UGIH
It is very uncertain whether erythromycin changes rebleeding compared with placebo (very low certainty).
1 finding from 1 review
Blood transfusion · people with acute UGIH
1 finding from 1 review
Reduction in itch score within 2 weeks, as rated by the participant · pityriasis rosea
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea
Erythromycin showed no clear difference in the proportion of participants with good or excellent rash… compared with placebo (low certainty).
1 finding from 1 review
Adverse events: minor gastrointestinal symptoms · pityriasis rosea
Erythromycin showed no clear difference in minor participant‐reported adverse events not requiring withdrawal… compared with placebo (moderate certainty).
1 finding from 1 review
The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea
1 finding from 1 review
The proportion of participants with resolution of itch within 2 weeks, as rated by the participant · pityriasis rosea
The review found no eligible studies for this question.
1 finding from 1 review